Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report

Y. Naomoto, H. Inoue, D. Hayashi, A. Gouchi, S. Fuchimoto, K. Sakagami, K. Orita

Research output: Contribution to journalArticle

Abstract

Hormonal chemotherapy in combination with cytokines was applied to a 45-year-old woman with mammary cancer complicated with systemic diffused bone metastasis. The patient received CAF therapy using Cyclo-Phosphamide (CPM), 5-fluorouracil (5-FU), and Pirarubicin (THP) as chemotherapy and Medroxyprogestrone (MPA) as hormonal therapy. In addition to these therapies, natural human interferon-α (nHuIFN-α) and natural human tumor necrosis factor-α (nHuTNF-α) were also administered. CPM (50 mg/day), 5-FU (100 mg/day), and MPA (60 mg/day) were orally administered consecutively. One shot of THP (20 mg) was intravenously administered ad libitum under monitoring the white blood cell number. At first, nHuIFN-α and nHuTNF-α were infused in a small amount and maintained the levels of 2 x 106 IU/day and 2,860 JRU/day, respectively. CA15-3, a tumor marker, gradually decreased soon after these treatments. Six months later, it decreased from 348.0 u/ml of pretreatments to 48 u/ml which is within normal value. In parallel with this decrease, metastatic tumors in the anterior chest and right axillae became markedly smaller, each slowing PR and CR, respectively. Eight months after the onset of the treatments, the tumor marker still maintained low level and general conditions of the patient was fairly improved. The prognosis of patients with breast cancer accompanied by systemic diffused bone metastasis is usually in a critical condition. In this case, however, hormonal chemotherapy combined with cytokines was effective on this kind of malignant cancer.

Original languageEnglish
Pages (from-to)1138-1142
Number of pages5
JournalJournal of Japan Society for Cancer Therapy
Volume26
Issue number6
Publication statusPublished - 1991

Fingerprint

Hormones
Breast Neoplasms
Cytokines
Neoplasm Metastasis
Bone and Bones
Dimethoate
Pharmaceutical Preparations
Tumor Biomarkers
Fluorouracil
Interferons
Therapeutics
Drug Therapy
Axilla
Blood Cell Count
Combination Drug Therapy
Neoplasms
Reference Values
Leukocytes
Thorax
human TNF protein

ASJC Scopus subject areas

  • Cancer Research

Cite this

Naomoto, Y., Inoue, H., Hayashi, D., Gouchi, A., Fuchimoto, S., Sakagami, K., & Orita, K. (1991). Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report. Journal of Japan Society for Cancer Therapy, 26(6), 1138-1142.

Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report. / Naomoto, Y.; Inoue, H.; Hayashi, D.; Gouchi, A.; Fuchimoto, S.; Sakagami, K.; Orita, K.

In: Journal of Japan Society for Cancer Therapy, Vol. 26, No. 6, 1991, p. 1138-1142.

Research output: Contribution to journalArticle

Naomoto, Y, Inoue, H, Hayashi, D, Gouchi, A, Fuchimoto, S, Sakagami, K & Orita, K 1991, 'Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report', Journal of Japan Society for Cancer Therapy, vol. 26, no. 6, pp. 1138-1142.
Naomoto, Y. ; Inoue, H. ; Hayashi, D. ; Gouchi, A. ; Fuchimoto, S. ; Sakagami, K. ; Orita, K. / Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report. In: Journal of Japan Society for Cancer Therapy. 1991 ; Vol. 26, No. 6. pp. 1138-1142.
@article{e3e8e80851ee4bc5b6dee714527647dc,
title = "Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report",
abstract = "Hormonal chemotherapy in combination with cytokines was applied to a 45-year-old woman with mammary cancer complicated with systemic diffused bone metastasis. The patient received CAF therapy using Cyclo-Phosphamide (CPM), 5-fluorouracil (5-FU), and Pirarubicin (THP) as chemotherapy and Medroxyprogestrone (MPA) as hormonal therapy. In addition to these therapies, natural human interferon-α (nHuIFN-α) and natural human tumor necrosis factor-α (nHuTNF-α) were also administered. CPM (50 mg/day), 5-FU (100 mg/day), and MPA (60 mg/day) were orally administered consecutively. One shot of THP (20 mg) was intravenously administered ad libitum under monitoring the white blood cell number. At first, nHuIFN-α and nHuTNF-α were infused in a small amount and maintained the levels of 2 x 106 IU/day and 2,860 JRU/day, respectively. CA15-3, a tumor marker, gradually decreased soon after these treatments. Six months later, it decreased from 348.0 u/ml of pretreatments to 48 u/ml which is within normal value. In parallel with this decrease, metastatic tumors in the anterior chest and right axillae became markedly smaller, each slowing PR and CR, respectively. Eight months after the onset of the treatments, the tumor marker still maintained low level and general conditions of the patient was fairly improved. The prognosis of patients with breast cancer accompanied by systemic diffused bone metastasis is usually in a critical condition. In this case, however, hormonal chemotherapy combined with cytokines was effective on this kind of malignant cancer.",
author = "Y. Naomoto and H. Inoue and D. Hayashi and A. Gouchi and S. Fuchimoto and K. Sakagami and K. Orita",
year = "1991",
language = "English",
volume = "26",
pages = "1138--1142",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - Successful therapy with cytokine, hormone and chemotherapeutic drugs for multiple bone metastasis of breast cancer. Case report

AU - Naomoto, Y.

AU - Inoue, H.

AU - Hayashi, D.

AU - Gouchi, A.

AU - Fuchimoto, S.

AU - Sakagami, K.

AU - Orita, K.

PY - 1991

Y1 - 1991

N2 - Hormonal chemotherapy in combination with cytokines was applied to a 45-year-old woman with mammary cancer complicated with systemic diffused bone metastasis. The patient received CAF therapy using Cyclo-Phosphamide (CPM), 5-fluorouracil (5-FU), and Pirarubicin (THP) as chemotherapy and Medroxyprogestrone (MPA) as hormonal therapy. In addition to these therapies, natural human interferon-α (nHuIFN-α) and natural human tumor necrosis factor-α (nHuTNF-α) were also administered. CPM (50 mg/day), 5-FU (100 mg/day), and MPA (60 mg/day) were orally administered consecutively. One shot of THP (20 mg) was intravenously administered ad libitum under monitoring the white blood cell number. At first, nHuIFN-α and nHuTNF-α were infused in a small amount and maintained the levels of 2 x 106 IU/day and 2,860 JRU/day, respectively. CA15-3, a tumor marker, gradually decreased soon after these treatments. Six months later, it decreased from 348.0 u/ml of pretreatments to 48 u/ml which is within normal value. In parallel with this decrease, metastatic tumors in the anterior chest and right axillae became markedly smaller, each slowing PR and CR, respectively. Eight months after the onset of the treatments, the tumor marker still maintained low level and general conditions of the patient was fairly improved. The prognosis of patients with breast cancer accompanied by systemic diffused bone metastasis is usually in a critical condition. In this case, however, hormonal chemotherapy combined with cytokines was effective on this kind of malignant cancer.

AB - Hormonal chemotherapy in combination with cytokines was applied to a 45-year-old woman with mammary cancer complicated with systemic diffused bone metastasis. The patient received CAF therapy using Cyclo-Phosphamide (CPM), 5-fluorouracil (5-FU), and Pirarubicin (THP) as chemotherapy and Medroxyprogestrone (MPA) as hormonal therapy. In addition to these therapies, natural human interferon-α (nHuIFN-α) and natural human tumor necrosis factor-α (nHuTNF-α) were also administered. CPM (50 mg/day), 5-FU (100 mg/day), and MPA (60 mg/day) were orally administered consecutively. One shot of THP (20 mg) was intravenously administered ad libitum under monitoring the white blood cell number. At first, nHuIFN-α and nHuTNF-α were infused in a small amount and maintained the levels of 2 x 106 IU/day and 2,860 JRU/day, respectively. CA15-3, a tumor marker, gradually decreased soon after these treatments. Six months later, it decreased from 348.0 u/ml of pretreatments to 48 u/ml which is within normal value. In parallel with this decrease, metastatic tumors in the anterior chest and right axillae became markedly smaller, each slowing PR and CR, respectively. Eight months after the onset of the treatments, the tumor marker still maintained low level and general conditions of the patient was fairly improved. The prognosis of patients with breast cancer accompanied by systemic diffused bone metastasis is usually in a critical condition. In this case, however, hormonal chemotherapy combined with cytokines was effective on this kind of malignant cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025864622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025864622&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0025864622

VL - 26

SP - 1138

EP - 1142

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 6

ER -